Drug interaction study for COPD inhaler: does cyclosporine change CHF6001 levels?
NCT ID NCT06892756
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study in 30 healthy volunteers looked at how cyclosporine, a drug that blocks certain transporters, affects the amount of CHF6001 (Tanimilast) in the blood. Participants took CHF6001 alone first, then again after taking cyclosporine. The goal was to see if cyclosporine changes CHF6001 levels, which could impact dosing for COPD patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CHF6001 (Tanimilast) dry powder inhaler and oral cyclosporine
What this could lead to
If successful, this study could help doctors understand how to safely combine CHF6001 with other drugs that affect transporters, potentially improving COPD treatment.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. It only measures drug levels, not effectiveness or safety for COPD. Results may not apply to real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical Centre Comac Medical Ltd
Sofia, 1612, Bulgaria